CYP19 Genetic Polymorphism Haplotype AASA Is Associated with a Poor Prognosis in Premenopausal Women with Lymph Node-Negative, Hormone Receptor-Positive Breast Cancer

Table 2

Association between various CYP19 genotypes and OS, DFS, or DDFS.

Genotype	OS		DFS		DDFS
	Hazard ratio (95% CI); aHR (95% CI)	𝑃	Hazard ratio (95% CI); aHR (95% CI)	𝑃	Hazard ratio (95% CI); aHR (95% CI)	𝑃
CYP19_rs4646 A/A + A/C versus C/C
Total; (𝑁=296)	1.6 (0.8–3.1); 1.8 (0.9–3.6)	0.17; 0.09	1.6 (1.0–2.5); 1.6 (1.0–2.6)	0.06; 0.06	1.6 (0.9–2.7); 1.7 (0.9–2.9)	0.10; 0.07
Premenopausal; (𝑛=178)	2.1 (0.9–4.9); 2.4 (1.0–5.9)	0.10; 0.06	1.8 (1.0–3.1); 1.8 (0.9–3.2)	0.05; 0.07	2.2 (1.1–4.4); 2.3 (1.1–4.9)	0.03; 0.02
Postmenopausal; (𝑛=118)	1.0 (0.3–2.9); 1.2 (0.4–3.7)	0.97; 0.81	1.3 (0.5–3.0); 1.4 (0.6–3.5)	0.59; 0.42	0.9 (0.3–2.2); 1.0 (0.4–2.7)	0.79; 0.99
Premenopausal patients receiving adjuvant chemotherapy (𝑛=86)	2.2 (0.6–7.4); 2.8 (0.7–10.7)	0.22; 0.13	1.8 (0.8–4.1); 1.7 (0.7–4.1)	0.15; 0.24	2.1 (0.8–5.4); 2.2 (0.8–6.3)	0.12; 0.13
CYP19_rs1065779 A/A + A/C versus C/C
Total; (𝑁=296)	1.3 (0.6–2.8); 1.6 (0.7–3.3)	0.50; 0.26	2.0 (1.1–3.6); 2.3(1.2–4.2)	0.02; 0.009	1.7 (0.9–3.2); 1.9 (1.0–3.7)	0.87; 0.06
Premenopausal; (𝑛=178)	2.2 (0.8–6.6); 2.6 (0.8–7.8)	0.15; 0.10	3.1 (1.4–6.8); 3.5 (1.5–7.9)	0.006; 0.003	2.9 (1.1–7.5); 3.2 (1.2–8.6)	0.03; 0.02
Postmenopausal; (𝑛=118)	0.5 (0.2–1.7); 0.7 (0.2–2.2)	0.29; 0.49	1.0 (0.4–2.5); 1.1 (0.4–3.0)	0.93; 0.84	0.7 (0.3–2.0); 0.9 (0.3–2.6)	0.56; 0.84
Premenopausal patients receiving adjuvant chemotherapy (𝑛=86)	4.1 (0.5–31.8); 7.0 (0.8–62.6)	0.18; 0.08	4.9 (1.1–20.7); 6.6 (1.5–29.4)	0.03; 0.01	7.0 (0.9–52.0); 13.0 (1.6–104.8)	0.06; 0.02
CYP19_(TTTA)n S/S + S/L versus L/L
Total; (𝑁=296)	2.8 (0.9–9.1); 3.3 (1.0–11.0)	0.09; 0.05	2.4 (1.1–5.3); 2.8 (1.3–6.2)	0.03; 0.01	2.4 (1.0–6.0); 2.8 (1.1–7.1)	0.06; 0.03
Premenopausal; (𝑛=178)	6.6 (0.9–48.7); 7.8 (1.0–58.9)	0.07; 0.05	3.6 (1.3–10.1); 4.0 (1.4–11.4)	0.01; 0.009	5.0 (1.2–20.7); 5.5 (1.3–23.5)	0.03; 0.02
Postmenopausal; (𝑛=118)	1.0 (0.2–4.5); 1.1 (0.2–5.1)	0.98; 0.93	1.2 (0.3–4.0); 1.3 (0.4–4.8)	0.81; 0.64	0.9 (0.3–3.1); 1.1 (0.3–4.1)	0.87; 0.86
Premenopausal patients receiving adjuvant chemotherapy (𝑛=86)	—; —		3.5 (0.8–15.1); 4.0 (0.9–17.9)	0.09; 0.07	5.3 (0.7–39.9); 6.3 (0.8–50.8)	0.10; 0.09
CYP19_rs1870050 A/A versus C/C + A/C
Total; (𝑁=296)	1.2 (0.6–2.3); 1.2 (0.6–2.4)	0.62; 0.53	1.3 (0.8–2.1); 1.4 (0.8–2.2)	0.31; 0.19	1.7 (1.0–2.9); 1.8 (1.0–3.1)	0.06; 0.05
Premenopausal; (𝑛=178)	1.7 (0.7–4.1); 1.9 (0.8–4.7)	0.22; 0.14	1.4 (0.8–2.4); 1.5 (0.8–2.8)	0.28; 0.17	1.9 (0.9–3.8); 2.1 (1.0–4.3)	0.07; 0.05
Postmenopausal; (𝑛=118)	0.6 (0.2–1.9); 0.6 (0.2–2.0)	0.41; 0.42	1.1 (0.5–2.5); 1.0 (0.4–2.4)	0.86; 0.99	1.3 (0.5–3.4); 1.2 (0.5–3.2)	0.54; 0.70
Premenopausal patients receiving adjuvant chemotherapy (𝑛=86)	1.8 (0.5–6.9); 2.1 (0.5–8.5)	0.37; 0.28	1.1 (0.5–2.6); 1.5 (0.6–3.7)	0.79; 0.40	2.7 (0.9–8.1); 3.3 (1.0–10.7)	0.08; 0.05